Back to Search Start Over

Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.

Authors :
Pau, Alice K
Pau, Alice K
Aberg, Judith
Baker, Jason
Belperio, Pamela S
Coopersmith, Craig
Crew, Page
Grund, Birgit
Gulick, Roy M
Harrison, Carly
Kim, Arthur
Lane, H Clifford
Masur, Henry
Sheikh, Virginia
Singh, Kanal
Yazdany, Jinoos
Tebas, Pablo
National Institutes of Health COVID-19 Treatment Guidelines Panel
Pau, Alice K
Pau, Alice K
Aberg, Judith
Baker, Jason
Belperio, Pamela S
Coopersmith, Craig
Crew, Page
Grund, Birgit
Gulick, Roy M
Harrison, Carly
Kim, Arthur
Lane, H Clifford
Masur, Henry
Sheikh, Virginia
Singh, Kanal
Yazdany, Jinoos
Tebas, Pablo
National Institutes of Health COVID-19 Treatment Guidelines Panel
Source :
Annals of internal medicine; vol 174, iss 1, 93-95; 0003-4819
Publication Year :
2021

Abstract

In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.

Details

Database :
OAIster
Journal :
Annals of internal medicine; vol 174, iss 1, 93-95; 0003-4819
Notes :
application/pdf, Annals of internal medicine vol 174, iss 1, 93-95 0003-4819
Publication Type :
Electronic Resource
Accession number :
edsoai.on1367379277
Document Type :
Electronic Resource